Table 1.
All | Survivors | Non-Survivors | p | |
---|---|---|---|---|
N | 479 | 350 | 129 | |
Age, years (median [IQR]) | 59.6 [46.7, 68.7] | 57.1 [44.1, 67.1] | 65.3 [55.8, 72.2] | <0.01 |
Men, n (%) | 256 (54.4) | 180 (52.6) | 76 (58.9) | 0.26 |
Whites, n (%) | 425 (90.2) | 307 (89.8) | 118 (91.5) | 0.67 |
BMI (median [IQR]) | 29.4 [25.5, 36.0] | 29.6 [25.5, 35.7] | 28.6 [25.3, 36.6] | 0.98 |
COPD, n (%) | 104 (22.1) | 75 (21.9) | 29 (22.5) | 1.00 |
Diabetes, n (%) | 168 (35.7) | 122 (35.7) | 46 (35.7) | 1.00 |
Alcohol use, n (%) | 84 (17.9) | 60 (17.5) | 24 (18.9) | 0.84 |
Immunosuppression, n (%) | 105 (22.3) | 71 (20.8) | 34 (26.4) | 0.24 |
ARDS, n (%) | 117 (25.2) | 81 (24.0) | 36 (28.1) | 0.23 |
WBC (median [IQR]) | 12.0 [8.7, 16.8] | 11.4 [8.1, 15.8] | 14.4 [10.1, 18.7] | <0.01 |
Creatinine (median [IQR]) | 1.2 [0.8, 2.3] | 1.1 [0.8, 2.0] | 1.6 [0.9, 2.5] | 0.01 |
Plateau Pressure (median [IQR]) | 20.0 [16.0, 25.0] | 19.0 [16.0, 24.0] | 22.0 [18.0, 27.0] | <0.01 |
PaO2:FiO2 ratio (median [IQR]) | 164.0 [117.0, 206.0] | 168.0 [121.5, 211.0] | 157.0 [108.0, 205.0] | 0.04 |
SOFA scores (median [IQR]) | 6.0 [4.0, 9.0] | 6.0 [4.0, 8.0] | 8.0 [5.0, 10.0] | <0.01 |
LIPS score (median [IQR]) | 5.5 [4.0, 6.5] | 5.0 [4.0, 6.5] | 6.0 [5.0, 7.5] | <0.01 |
Hypoinflammatory subphenotype, n (%) | 344 (75.6) | 254 (77.4) | 90 (70.9) | 0.18 |
VFD (median [IQR]) | 22.0 [13.0, 25.0] | 23.0 [20.0, 25.2] | 0.0 [0.0, 19.0] | <0.01 |
We compared continuous variables with non-parametric Wilcoxon tests and categorical variables with Fisher’s exact tests between the three groups. Statistically significant differences (p < 0.05) are highlighted in bold. Source data are provided as a Source Data file.
IQR Interquartile Range, BMI body mass index, COPD chronic obstructive pulmonary disease, LIPS lung injury prediction score, WBC white blood cell count, PaO2 partial pressure of arterial oxygen, FiO2 Fractional inhaled concentration of oxygen, SOFA sequential organ failure assessment, VFD ventilator free days, ARDS acute respiratory distress syndrome. Immunosuppression was broadly defined as receipt of chronic steroids, alkylating agents, antimetabolites, biologics, calcineurin inhibitors, mycophenolate, active chemotherapy for cancer, or diagnosis of untreated immunodeficiency.